Lewes, DE -- (SBWIRE) -- 07/10/2013 -- LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: Federal National Mortgage Association (OTCBB:FNMA), AMR Corporation (OTCMKTS:AAMRQ), Federal Home Loan Mortgage Corp (OTCBB:FMCC), Arch Therapeutics Inc (OTCBB:ARTH)
Federal National Mortgage Association (OTCBB:FNMA) declined -6.36%, trading on 21.08 million shares to end the trade at $1.62. The stock changed hands in a range of $1.62 to $1.78, bringing its market capitalization at about $2.78 billion. If we look at its trading history of past 52 weeks, the share price suffered low of $0.20 and was moved to maximum level of $5.44. Federal National Mortgage Association (Fannie Mae) provides liquidity and stability support services in the secondary mortgage market in the United States. The company securitizes mortgage loans originated by lenders in the primary mortgage market into Fannie Mae mortgage-backed securities (Fannie Mae MBS).
Has FNMA Found The Bottom and Ready To Move Up? Find Out Here
AMR Corporation (OTCMKTS:AAMRQ) added 9.77% to complete the trading session at $4.72 with a total volume of 5.82 million shares. The stock, on average, trades on a volume of 5.28 million shares. It floated in a range of $4.33 to $4.75 during last trading session with a beta value of 1.81. Its market capitalization now moved to about $1.58 billion. In the past 52 weeks, the share price has not declined below $0.36 and above $7.15. AMR Corporation reported June 2013 consolidated revenue and traffic results for its principal subsidiary, American Airlines, Inc., and its wholly owned subsidiary, AMR Eagle Holding Corporation.
What was the Moving Force behind AAMRQ on Bullish Run? Read This Research Report
Federal Home Loan Mortgage Corp (OTCBB:FMCC) recorded a fall of -3.75% and was in a range of $1.54-$1.65 before closing at $1.54. The stock completed the day with a total volume of 7.85 million shares versus an average volume of 28.29 million shares. The share price hit its 52-week low of $0.14 and $5.00 was the best price. Federal Home Loan Mortgage Corporation provides credit guarantee for residential mortgages originated by mortgage lenders and invests in mortgage loans and mortgage-related securities in the United States. It operates in three segments: Single-Family Guarantee, Investments, and Multifamily.
Has FMCC Found The Bottom And Ready To Gain Momentum? Find Out Here
Arch Therapeutics Inc (OTCBB:ARTH) added 4.84% yesterday, bringing its market capitalization around $57.20 million. The share price after opening at $1.30 made a high of $1.32 and hovered above $1.23 to end the day at $1.30. The total number of shares changed hands during the session was 3.75 million shares as compared to average trading volume of 597,793 shares. Arch Therapeutics, Inc. (ARTH) a life science company and developer of AC5™, a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to appoint Mr. Alan Barber as CFO and Mr. William M. Cotter as COO.
For How Long ARTH will fight for Profitability? Read This Trend Analysis report
About LeadingStockAlerts:
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.
Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.
Disclaimer:
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/